TScan Therapeutics (TCRX) Stock Forecast & Price Target

TScan Therapeutics is currently undergoing a strategic reorganization, pausing further enrollment in their Ph 3 ALLOHA-2 study of TSC-101 despite positive early clinical data and redirecting their efforts towards two preclinical in vivo-engineered TCR-T programs targeting PRAME and MAGE-A4. As a result, the stock is now trading based on cash burn and potential strategic optionality, rather than the probability of successful data maturation and potential Phase 3 topline readout. While the financial constraints may limit their ability to complete IND-enabling studies within the proposed timeline, management has noted previous experience with rapid development and has announced potential IND submission in 3Q:27 and Phase I initiation in 4Q:27. Therefore, we remain confident in the sophisticated scientific foundation of the heme program and the potential of the solid tumor pipeline, although we are downgrading TCRX to NEUTRAL and lowering our PT to $1 (from $5) due to the shift from a late-stage clinical asset to an unvalidated in vivo platform.

TScan Therapeutics is a fully integrated clinical-stage biotechnology company currently facing significant challenges in its development and financial outlook. The recent decision to pause enrollment in the Phase 3 ALLOHA-2 study due to insufficient capital significantly changes the investment thesis and casts doubt on the company's ability to bring its most clinically advanced asset, TSC-101, to market. The company's efforts to redirect resources towards earlier stage candidates, specifically their in vivo engineered TCR-T candidates targeting PRAME and MAGE-A4, also create substantial uncertainty around the timing and success of their development. This, combined with the typical risks associated with investing in a development-stage biotechnology company, leads to a negative outlook on TScan's stock.